step 6 semaglutide Once-weekly 2·4 mg in an Asian population with obesity, defined as BMI ≥25 kg/m2, in South Korea and Thailand (STEP 11): a randomised, double-blind, placebo-controlled, phase 3 trial Semaglutide dosing guidelines for 2026

or better yet, consult a board-certified dermatologist about proven alternatives

Clinical recommendations to manage gastrointestinal adverse events in patients treated with glp-1 receptor agonists: a multidisciplinary expert consensus

Any attempt to copy clinical dosing outside trials is unsafe and illegal

McGuire DK, Busui RP, Deanfield J, Inzucchi SE, Mann JFE, Marx N, Mulvagh SL, Poulter N, Engelmann MDM, Hovingh GK, Ripa MS, Gislum M, Brown-Frandsen K, Buse JB

It is also approved for chronic weight management in obese or overweight adults with at least one weight-related comorbidity, such as hypertension, dyslipidemia, or type 2 diabetes, providing both metabolic and cardiovascular benefits